TW202310868A - 用於治療眼睛疾病的生長因子組合物 - Google Patents

用於治療眼睛疾病的生長因子組合物 Download PDF

Info

Publication number
TW202310868A
TW202310868A TW111118098A TW111118098A TW202310868A TW 202310868 A TW202310868 A TW 202310868A TW 111118098 A TW111118098 A TW 111118098A TW 111118098 A TW111118098 A TW 111118098A TW 202310868 A TW202310868 A TW 202310868A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
gly
polypeptide
Prior art date
Application number
TW111118098A
Other languages
English (en)
Chinese (zh)
Inventor
皮奧塔 布萊拉
蘇珊 Ｃ 奧爾
Ａ 克拉克 艾特沃
Original Assignee
美商克拉里斯生物醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商克拉里斯生物醫療股份有限公司 filed Critical 美商克拉里斯生物醫療股份有限公司
Publication of TW202310868A publication Critical patent/TW202310868A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW111118098A 2021-05-14 2022-05-13 用於治療眼睛疾病的生長因子組合物 TW202310868A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163188816P 2021-05-14 2021-05-14
US63/188,816 2021-05-14

Publications (1)

Publication Number Publication Date
TW202310868A true TW202310868A (zh) 2023-03-16

Family

ID=81756753

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118098A TW202310868A (zh) 2021-05-14 2022-05-13 用於治療眼睛疾病的生長因子組合物

Country Status (12)

Country Link
US (1) US20230022990A1 (cg-RX-API-DMAC10.html)
EP (2) EP4337243A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518178A (cg-RX-API-DMAC10.html)
KR (1) KR20240035394A (cg-RX-API-DMAC10.html)
CN (1) CN117677394A (cg-RX-API-DMAC10.html)
AU (1) AU2022272740A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023022474A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218000A1 (cg-RX-API-DMAC10.html)
IL (1) IL308496A (cg-RX-API-DMAC10.html)
MX (1) MX2023012782A (cg-RX-API-DMAC10.html)
TW (1) TW202310868A (cg-RX-API-DMAC10.html)
WO (1) WO2022241465A1 (cg-RX-API-DMAC10.html)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5510329A (en) * 1988-04-26 1996-04-23 Ramot University For Applied Research And Industrial Development Ltd. Preparations for the treatment of eyes
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
JP2000344680A (ja) * 1999-05-31 2000-12-12 Mitsubishi Chemicals Corp Ｈｇｆ含有医薬組成物
WO2004026244A2 (en) * 2002-09-18 2004-04-01 Emiliano Ghinelli Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US8895508B2 (en) * 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
KR102291913B1 (ko) * 2014-04-28 2021-08-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆ의 동결건조 제제
DK3192524T3 (da) 2014-09-10 2022-02-14 Kringle Pharma Inc Hgf præparat egnet til behandling af neurologiske lidelser
JP6929273B2 (ja) * 2015-09-11 2021-09-01 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN116710568A (zh) * 2020-06-26 2023-09-05 特里福伊尔治疗公司 重组修饰成纤维细胞生长因子及其治疗用途

Also Published As

Publication number Publication date
IL308496A (en) 2024-01-01
CN117677394A (zh) 2024-03-08
US20230022990A1 (en) 2023-01-26
KR20240035394A (ko) 2024-03-15
AU2022272740A9 (en) 2023-11-09
JP2024518178A (ja) 2024-04-25
BR112023022474A2 (pt) 2024-01-09
WO2022241465A1 (en) 2022-11-17
CA3218000A1 (en) 2022-11-17
EP4574211A2 (en) 2025-06-25
MX2023012782A (es) 2024-03-25
EP4574211A3 (en) 2025-09-10
EP4337243A1 (en) 2024-03-20
AU2022272740A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
US6238888B1 (en) Keratinocyte growth factor-2 formulations
JPH10158188A (ja) 角膜治療用組成物
JP2003512433A (ja) 角膜欠陥を処置するためのｇｄｎｆの使用
US12318428B2 (en) VEGFR fusion protein pharmaceutical composition
CN111148755A (zh) 重组经修饰成纤维细胞生长因子及其治疗用途
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
WO2014084027A1 (ja) 細胞膜透過性の線維芽細胞増殖因子の医療用途
Jiang et al. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2
KR20220047979A (ko) 안구 건조증에 대한 tsg6 폴리펩티드 단편
CA3083101A1 (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
US20230022990A1 (en) Compositions of growth factor for the treatment of eye disease
JP2024533245A (ja) Ｖｅｇｆ受容体融合タンパク質の製剤
US20250002557A1 (en) Multi-specific ligand-binding molecules and applications thereof
HK40128523A (en) Compositions of growth factor for the treatment of eye disease
US20080132451A1 (en) Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
US8207119B2 (en) Ophthalmological composition
CA3147828C (en) Agent for use in treatment or prevention of ophthalmic disorders
CN107428805A (zh) 短合成肽及其治疗和/或预防干眼症的用途
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
WO2025140553A1 (zh) 一种含有抗vegf的融合蛋白的药物组合物
HK40116769A (en) Multispecific ligand binding molecule and application thereof